Low-dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy

被引:43
作者
Ballen, KK
Becker, PS
Emmons, RVB
Fitzgerald, TJ
Hsieh, CC
Liu, Q
Heyes, C
Clark, Y
Levy, W
Lambert, JF
Chiafari, F
Szymanski, I
Rososhansky, S
Popovsky, MA
Stewart, FM
Quesenberry, PJ
机构
[1] Univ Massachusetts Mem Hlth Care, Ctr Canc, Worcester, MA USA
[2] Univ Massachusetts Mem Hlth Care, Dept Med, Worcester, MA USA
[3] Univ Massachusetts Mem Hlth Care, Dept Radiat Oncol, Worcester, MA USA
[4] Univ Massachusetts Mem Hlth Care, Dept Pathol, Worcester, MA USA
[5] Baltimore Rh Typing Lab, Baltimore, MD USA
[6] American Red Cross, Cord Blood Program, Dedham, MA USA
关键词
D O I
10.1182/blood.V100.2.442
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Allogeneic stem cell transplantation is curative for certain cancers, but the high doses of chemotherapy/radiotherapy lead to toxicity. Here, we treat patients with refractory cancer with 100 cGy total body irradiation (TBI) followed by infusion of nonmobilized pheresed allogeneic peripheral blood cells. Twenty-five patients, with a median age of 47 years, with refractory cancers were enrolled. Eighteen patients received sibling and 7 received unrelated cord blood cells. Donor chimerism was assessed at weeks 1, 2, 3, 4, and 8 after transplantation. Seven patients with solid tumors received a sibling transplant and 6 received a cord blood transplant; none achieved donor chimerism, but 1 treated at the higher dose level of 1 x 108 CD3(+) cells/kg had a transient nodal response. Twelve patients with hematologic malignancies were treated; 1 received a cord blood transplant and 11 received sibling donor cells. Nine of these 11 patients achieved donor chimerism, ranging from 5% to 100%. Four patients had sustained complete remission of their cancers, including one patient with transient 5% donor chimerism. The development of chimerism correlated with hematologic malignancy (P <.001), total previous myelotoxic chemotherapy (P <.001), T-cell dose (P=.03), and graft-versus-host disease (P=.01). Tumor response correlated with donor chimerism (P=.01). Engraftment was achieved In patients with hematologic malignancies who had been heavily pretreated, suggesting the degree of immunosuppression may be a determinant of engraftment. Low-dose TBI and allogeneic lymphocyte Infusion may Induce remission In patients with refractory hematologic malignancy. (Blood. 2002; 100:442-450). (C) 2002 by The American Society of Hematology.
引用
收藏
页码:442 / 450
页数:9
相关论文
共 47 条
[11]   Total body irradiation and acute graft-versus-host disease: The role of gastrointestinal damage and inflammatory cytokines [J].
Hill, GR ;
Crawford, JM ;
Cooke, KR ;
Brinson, YS ;
Pan, LY ;
Ferrara, JLM .
BLOOD, 1997, 90 (08) :3204-3213
[12]  
Keating S, 1996, BONE MARROW TRANSPL, V17, P993
[13]   Reduction in the frequency of transplant-related complications in patients with chronic myeloid leukemia undergoing BMT preconditioned with a new, non-myeloablative drug combination [J].
Kelemen, E ;
Masszi, T ;
Reményi, P ;
Barta, A ;
Pálóczi, K .
BONE MARROW TRANSPLANTATION, 1998, 21 (08) :747-749
[14]  
KELLOGG DE, 1994, BIOTECHNIQUES, V16, P1134
[15]   ANALYSIS OF 462 TRANSPLANTATIONS FROM UNRELATED DONORS FACILITATED BY THE NATIONAL-MARROW-DONOR-PROGRAM [J].
KERNAN, NA ;
BARTSCH, G ;
ASH, RC ;
BEATTY, PG ;
CHAMPLIN, R ;
FILIPOVICH, A ;
GAJEWSKI, J ;
HANSEN, JA ;
HENSLEEDOWNEY, J ;
MCCULLOUGH, J ;
MCGLAVE, P ;
PERKINS, HA ;
PHILLIPS, GL ;
SANDERS, J ;
STRONCEK, D ;
THOMAS, ED ;
BLUME, KG .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (09) :593-602
[16]   Transplant-lite:: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies [J].
Khouri, IF ;
Keating, M ;
Körbling, M ;
Przepiorka, D ;
Anderlini, P ;
O'Brien, S ;
Giralt, S ;
Ippoliti, C ;
von Wolff, B ;
Gajewski, J ;
Donato, M ;
Claxton, D ;
Ueno, N ;
Andersson, B ;
Gee, A ;
Champlin, R .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2817-2824
[17]  
Khoury H, 1999, BLOOD, V94, p393A
[18]  
KLINGEMANN HG, 1986, BLOOD, V67, P770
[19]  
Kogler G, 1996, J Hematother, V5, P105, DOI 10.1089/scd.1.1996.5.105
[20]   GRAFT-VERSUS-LEUKEMIA EFFECT OF DONOR LYMPHOCYTE TRANSFUSIONS IN MARROW GRAFTED PATIENTS [J].
KOLB, HJ ;
SCHATTENBERG, A ;
GOLDMAN, JM ;
HERTENSTEIN, B ;
JACOBSEN, N ;
ARCESE, W ;
LJUNGMAN, P ;
FERRANT, A ;
VERDONCK, L ;
NIEDERWIESER, D ;
VANRHEE, F ;
MITTERMUELLER, J ;
DEWITTE, T ;
HOLLER, E ;
ANSARI, H .
BLOOD, 1995, 86 (05) :2041-2050